Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Enterprise Value (2016 - 2025)

Adma Biologics (ADMA) has disclosed Enterprise Value for 14 consecutive years, with -$87.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value rose 15.04% year-over-year to -$87.6 million, compared with a TTM value of -$87.6 million through Dec 2025, up 15.04%, and an annual FY2025 reading of -$87.6 million, up 15.04% over the prior year.
  • Enterprise Value was -$87.6 million for Q4 2025 at Adma Biologics, down from -$61.4 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$34.4 million in Q3 2021 and bottomed at -$103.1 million in Q4 2024.
  • Average Enterprise Value over 5 years is -$66.2 million, with a median of -$65.9 million recorded in 2023.
  • The sharpest move saw Enterprise Value soared 42.35% in 2021, then crashed 112.61% in 2023.
  • Year by year, Enterprise Value stood at -$51.1 million in 2021, then tumbled by 69.36% to -$86.5 million in 2022, then surged by 40.65% to -$51.4 million in 2023, then tumbled by 100.86% to -$103.1 million in 2024, then grew by 15.04% to -$87.6 million in 2025.
  • Business Quant data shows Enterprise Value for ADMA at -$87.6 million in Q4 2025, -$61.4 million in Q3 2025, and -$90.3 million in Q2 2025.